dual agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-26. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
== Enhanced chemiluminescence == Enhanced chemiluminescence (ECL) is a common technique for a variety of detection assays in biology. A horseradish peroxidase enzyme (HRP) is tethered to an antibody that specifically recognizes the molecule of interest. This enzyme complex then catalyzes the conversion of the enhanced chemiluminescent substrate into a sensitized reagent in the vicinity of the molecule of interest, which on further oxidation by hydrogen peroxide, produces a triplet (excited) carbonyl, which emits light when it decays to the singlet carbonyl. Enhanced chemiluminescence allows detection of minute quantities of a biomolecule. Proteins can be detected down to femtomole quantities, well below the detection limit for most assay systems.
Dr. Gian Parkash Gopal. Founder, Oxford Hindu Temple and Community Centre Project. For services to the Hindu Community and to Multi-Faith Cohesion in Oxfordshire. Elizabeth Jane Gorb. Director of Apprenticeships, Manchester Metropolitan University. For services to Education and Skills. Permjit Gosal (Pam Gosal), MSP. Member of the Scottish Parliament for West Scotland. For services to Business, to Racial Equality and to Charity in Milton Keynes. David James Connelly Graham. National Director, Care Leavers Association. For services to Care Leavers. Sarah Jane Vandevelde Graham. Founder, Hilltops Ukrainian Support Community. For services to Ukrainian Refugees. The Reverend Canon Terence Kevin Declan Graham, DL. Rector, St Bartholomew's Church, Belfast. For services to the Reserve Forces and to the community in Belfast. Julie Grant. Deputy Director, News and Digital, Scottish Government. For services to Scotland on the Demise of Her Majesty Queen Elizabeth II. Dr. Simon Jonathon Grant. Technical Director, Thomas Swan. For services to Diversity in the Chemical Industry. Belinda Elizabeth Gray. Founder, Art for Cure. For services to Breast Cancer Charities. Julie Heather Gray. Founder, Adventure Activities for All Abilities. For services to Children with Impairments in Nottinghamshire. Neil Jonathan Greenwood. Executive Director, Finance and Corporate Services, Natural History Museum. For services to Museums. Robert Terence Grey. Lately Boxing Gym Owner and Trainer, Gwent Amateur Boxing Club. For services to Amateur Boxing in Swansea. Dr. John Michael Grimshaw.
== Laboratory directors == Clinical laboratories in the US that perform high complexity testing require a high complexity laboratory director (HCLD) who has earned a doctoral degree in chemical, physical, biological, or clinical laboratory science from an accredited institution and is certified by, and remains certified by, a board approved by HHS. The current approved boards are the following:
==== Regioselective disulfide bond formation ==== The formation of multiple native disulfides remains challenging for native peptide synthesis by solid-phase methods. Random chain combination typically results in several products with nonnative disulfide bonds. Stepwise formation of disulfide bonds is typically the preferred method, and performed with thiol protecting groups. Different thiol protecting groups provide multiple dimensions of orthogonal protection. These orthogonally protected cysteines are incorporated during the solid-phase synthesis of the peptide. Successive removal of these groups, to allow for selective exposure of free thiol groups, leads to disulfide formation in a stepwise manner. The order of removal of the groups must be considered so that only one group is removed at a time. Thiol protecting groups used in peptide synthesis requiring later regioselective disulfide bond formation must possess multiple characteristics. First, they must be reversible with conditions that do not affect the unprotected side chains. Second, the protecting group must be able to withstand the conditions of solid-phase synthesis. Third, the removal of the thiol protecting group must be such that it leaves intact other thiol protecting groups, if orthogonal protection is desired. That is, the removal of PG A should not affect PG B. Some of the thiol protecting groups commonly used include the acetamidomethyl (Acm), tert-butyl (But), 3-nitro-2-pyridine sulfenyl (NPYS), 2-pyridine-sulfenyl (Pyr), and trityl (Trt) groups.
Sources: en.wikipedia.org
Duterte also used the US-Philippines Visiting Forces Agreement as leverage in securing vaccines from the United States, threatening to scrap the military pact. In addition, in an apparent effort to help the Philippines gain access to US-developed vaccines, Duterte granted absolute pardon to US soldier Joseph Scott Pemberton, who was serving prison for killing transgender Jennifer Laude in 2014.
=== Magic Pill (2024) === Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight Loss Drugs, Hari's first-person account of taking the weight loss drug Ozempic (semaglutide), was published in 2024. The book also documents the history of the medication. According to Hari, while there are health benefits to taking Ozempic for some users, there are also potential risks. Hari falsely claimed in Magic Pill that restaurant critic Jay Rayner had taken semaglutide and the book included false statements about Rayner's opinion of the drug. Rayner had previously written that he would never take the drug, and described Hari's description as "very much defamatory". Hari apologized for the error. In a review for The Guardian, science writer Tom Chivers found several misuses of references that did not support the book's claims, as well as scientific inaccuracies. A fact check by The Daily Telegraph found six examples of "errors, outdated data and disputed claims". Hari said these errors would be corrected in future editions. Magic Pill has been translated into French and Russian.
Progesterone is available in a variety of different forms, including oral capsules; sublingual tablets; vaginal capsules, tablets, gels, suppositories, and rings; rectal suppositories; oil solutions for intramuscular injection; and aqueous solutions for subcutaneous injection. A 1% topical progesterone gel is approved for local application to the breasts to treat breast pain, but is not indicated for systemic therapy. Progesterone was previously available as an intrauterine device for use in hormonal contraception, but this formulation was discontinued. Progesterone is also limitedly available in combination with estrogens such as estradiol and estradiol benzoate for use by intramuscular injection. In addition to approved pharmaceutical products, progesterone is available in unregulated custom compounded and over-the-counter formulations like systemic transdermal creams and other preparations. The systemic efficacy of transdermal progesterone is controversial and has not been demonstrated.
Sources: en.wikipedia.org
Acetone peroxide ( also called APEX and mother of Satan) is an organic peroxide and a primary explosive. It is produced by the reaction of acetone, hydrogen peroxide and a strong acidic catalyst to yield a mixture of linear monomer and cyclic dimer, trimer, and tetramer forms. The monomer is dimethyldioxirane. The dimer is known as diacetone diperoxide (DADP). The trimer is known as triacetone triperoxide (TATP) or tri-cyclic acetone peroxide (TCAP). Acetone peroxide takes the form of a white crystalline powder with a distinctive bleach-like odor when impure, or a fruit-like smell when pure, and can explode powerfully if subjected to heat, friction, static electricity, concentrated sulfuric acid, strong UV radiation, or shock. Until about 2015, explosives detectors were not set to detect non-nitrogenous explosives, as most explosives used preceding 2015 were nitrogen-based. TATP, being nitrogen-free, has been used as the explosive of choice in several terrorist bomb attacks since 2001.
When a beer has been brewed using a cool fermentation of around 10 °C (50 °F), compared to typical warm fermentation temperatures of 18 °C (64 °F), then stored (or lagered) for typically several weeks (or months) at temperatures close to freezing point, it is termed a "lager". During the lagering or storage phase several flavour components developed during fermentation dissipate, resulting in a "cleaner" flavour. Though it is the slow, cool fermentation and cold conditioning (or lagering) that defines the character of lager, the main technical difference is with the yeast generally used, which is Saccharomyces pastorianus. Technical differences include the ability of lager yeast to metabolise melibiose, and the tendency to settle at the bottom of the fermenter (though ale yeasts can also become bottom settling by selection); though these technical differences are not considered by scientists to be influential in the character or flavour of the finished beer, brewers feel otherwise – sometimes cultivating their own yeast strains which may suit their brewing equipment or for a particular purpose, such as brewing beers with a high abv.
After the war, Stalin sought to secure the Soviet Union's western border by installing communist-dominated regimes under Soviet influence in bordering countries. During and in the years immediately after the war, the Soviet Union annexed several countries as Soviet Socialist Republics within the Union of Soviet Socialist Republics. Many of these were originally countries effectively ceded to it by Nazi Germany in the Molotov–Ribbentrop Pact, before Germany invaded the Soviet Union. These later annexed territories include Eastern Poland (incorporated into two different SSRs), Latvia (became Latvia SSR), Estonia (became Estonian SSR), Lithuania (became Lithuania SSR), part of eastern Finland (Karelo-Finnish SSR and annexed into the Russian SFSR) and northern Romania (became the Moldavian SSR). In Hungary, when the Soviets installed a communist government, Mátyás Rákosi was appointed General Secretary of the Hungarian Communist Party, which began one of the harshest dictatorships in Europe under the People's Republic of Hungary. In Bulgaria, toward the end of World War II, the Soviet Union crossed the border and created the conditions for a communist coup d'état on the following night. The Soviet military commander in Sofia assumed supreme authority, and the communists whom he instructed, including Kimon Georgiev (who was not a communist himself, but a member of the elitarian political organization "Zveno", working together with the communists), took full control of domestic politics in the People's Republic of Bulgaria.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.